Outbreak of Mucormycosis in Coronavirus Disease Patients,Pune, India |
| |
| Authors: | Samir Joshi Rahul Telang Muralidhar Tambe Rajesh Havaldar Manasi Sane Afshan Shaikh Cherry Roy Kireet Yathati Sanjaykumar Sonawale Rupalee Borkar Rahul Magar Harshal Bhitkar Satish Shitole Leena Nakate Jyoti Kudrimoti Vidya Mave |
| |
| Affiliation: | Byramjee-Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India (S. Joshi, R. Telang, M. Tambe, R. Havaldar, A. Shaikh, C. Roy, K. Yathati, S. Sonawale, R. Borkar, R. Magar, H. Bhitkar, S. Shitole, L. Nakate, J. Kudrimoti);Byramjee-Jeejeebhoy Government Medical College—Johns Hopkins University Clinical Research Site, Pune (S. Joshi, M. Sane, V. Mave) |
| |
| Abstract: | ![]()
We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confirmed rhino-sino-orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis. |
| |
| Keywords: | COVID-19 SARS-CoV-2 coronavirus disease 2019 severe acute respiratory syndrome coronavirus 2 viruses respiratory infections zoonoses invasive mucormycosis fungal infections fungi rhino-sino-orbital mucormycosis India |
|
|
